<DOC>
	<DOCNO>NCT02631928</DOCNO>
	<brief_summary>This study healthy volunteer aim demonstrate similar PK PD property new human biphasic insulin , Julphar Insulin 30/70 already approve reference insulin , Huminsulin速 Profil III . All participant receive study treatment two separate dosing day .</brief_summary>
	<brief_title>Pharmacokinetic ( PK ) Bioequivalence Pharmacodynamics ( PD ) Julphar Insulin 30/70 Huminsulin速 Profil III</brief_title>
	<detailed_description>Daily injection insulin necessity many patient diabetes mellitus order treat hyperglycaemia . Julphar Insulin 30/70 Humininsulin速 Profil III biphasic insulin , i.e . consist mixture short-acting soluble insulin intermediate-acting isophane insulin . The new insulin , Julphar Insulin 30/70 , biosimilar Huminsulin速 Profil III . Demonstration similar absorption ( PK ) effect ( PD ) necessary achieve market approval Julphar Insulin 30/70 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<criteria>Signed date informed consent obtain trialrelated activity . ( Trialrelated activity procedure would perform normal management subject ) . Healthy male subject . Age 18 55 year , inclusive . Body Mass Index ( BMI ) 18.5 28.0 kg/m^2 , inclusive . Fasting plasma glucose concentration &lt; = 100 mg/dL . Known suspected hypersensitivity IMPs related product . Previous participation trial . Participation define randomise . Receipt medicinal product clinical development within 3 month screen . Any history presence cancer except basal cell skin cancer squamous cell skin cancer judge Investigator . Any history presence clinically relevant cardiovascular , pulmonary , respiratory , gastrointestinal , hepatic , renal , metabolic , endocrinological haematological , dermatological , neurological , osteomuscular , articular , psychiatric , systemic , ocular , infectious disease , sign acute illness judge Investigator . Surgery within 12 week start study blood donation 500 mL ( considerable blood loss ) plasma donation within last 3 month . Increased risk thrombosis , e.g. , subject history deep leg vein thrombosis family history deep leg vein thrombosis , judge Investigator . Clinically significant abnormal value haematology , biochemistry , coagulation , urinalysis judge Investigator . Supine blood pressure ( BP ) screening ( rest 5 minute supine position ) outside range 90 140 mmHg systolic BP 50 90 mmHg diastolic BP ( exclude whitecoat hypertension ; therefore , repeat measurement show value within range , subject include trial ) and/or rest supine pulse &lt; 50 beat per minute . Clinically significant abnormal standard 12lead electrocardiogram ( ECG ) 5 minute rest supine position screening , judge Investigator . Any disease condition , opinion Investigator , would represent unacceptable risk subject 's safety . Positive screen test Hepatitis Bs antigen Hepatitis C antibodies and/or positive result test HIV1/2 antibodies HIV1 antigen . History multiple and/or severe allergy drug food history severe anaphylactic reaction . Likelihood require treatment study period drug permit clinical study protocol . Any medication ( prescription nonprescription drug ) within 14 day first trial drug administration and/or anticoagulant therapy , exception stable treatment thyroid hormone , paracetamol ibuprofen occasional use treat pain . Significant history alcoholism drug abuse judge Investigator consume 21 unit alcohol per week ( one unit alcohol equal 330 mL beer , one glass wine 120 mL , 40 mL spirit ) . A positive result alcohol and/or urine drug screen screen visit . Smoker ( define subject smoke 5 cigarette equivalent per day ) able willing refrain smoking use nicotine substitute product 1 day inpatient period . Subject mental incapacity language barrier preclude adequate understanding cooperation , opinion Investigator , participate trial . Potentially noncompliant uncooperative trial , judge Investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>biphasic human insulin</keyword>
	<keyword>biosimilar</keyword>
</DOC>